WO2011160096A3 - Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition - Google Patents
Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition Download PDFInfo
- Publication number
- WO2011160096A3 WO2011160096A3 PCT/US2011/040998 US2011040998W WO2011160096A3 WO 2011160096 A3 WO2011160096 A3 WO 2011160096A3 US 2011040998 W US2011040998 W US 2011040998W WO 2011160096 A3 WO2011160096 A3 WO 2011160096A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- autoantibodies
- biomarkers
- condition
- autoantigens
- neurological disorder
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Abstract
The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of one or more autoantibodies to biomarkers in a biological fluid such as CSF or serum for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35577910P | 2010-06-17 | 2010-06-17 | |
US61/355,779 | 2010-06-17 | ||
US201161476158P | 2011-04-15 | 2011-04-15 | |
US61/476,158 | 2011-04-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/048789 Continuation-In-Part WO2011032155A2 (en) | 2009-09-14 | 2010-09-14 | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
US13/395,931 Continuation-In-Part US20130022982A1 (en) | 2009-09-14 | 2010-09-14 | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011160096A2 WO2011160096A2 (en) | 2011-12-22 |
WO2011160096A3 true WO2011160096A3 (en) | 2012-04-26 |
Family
ID=45348920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/040998 WO2011160096A2 (en) | 2010-06-17 | 2011-06-17 | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011160096A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5909447B2 (en) | 2009-09-14 | 2016-04-26 | バンヤン・バイオマーカーズ・インコーポレーテッド | MicroRNAs, autoantibodies and protein markers for neuronal damage diagnosis |
US11402379B2 (en) | 2016-09-09 | 2022-08-02 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating autoimmune GFAP astrocytopathy |
US11061027B2 (en) | 2016-09-27 | 2021-07-13 | Mayo Foundation For Medical Education And Research | Materials and methods for evaluating and treating cancer |
WO2018132639A1 (en) * | 2017-01-13 | 2018-07-19 | Foster Charles Stephen | Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid |
US10345302B2 (en) * | 2017-02-19 | 2019-07-09 | Sheng-He Huang | Circulating astrocytes and MFSD2A as biomarkers |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
CN110546513A (en) | 2017-04-15 | 2019-12-06 | 雅培实验室 | Methods for using early biomarkers to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects |
EP3635407A1 (en) | 2017-04-28 | 2020-04-15 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
CN110651190A (en) | 2017-05-25 | 2020-01-03 | 雅培实验室 | Method for using early biomarkers to help determine whether to perform imaging on a human subject who has suffered or may have suffered a head injury |
AU2018275235A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
WO2019010131A1 (en) | 2017-07-03 | 2019-01-10 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
CN107629112B (en) * | 2017-09-07 | 2020-10-27 | 北京大学 | High-affinity LC3 protein targeting peptide and application thereof |
EP3721234A1 (en) | 2017-12-09 | 2020-10-14 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
CN111094983A (en) | 2017-12-09 | 2020-05-01 | 雅培实验室 | Methods of using Glial Fibrillary Acidic Protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1(UCH-L1) to aid in the diagnosis and evaluation of patients who have suffered orthopedic injury and who have suffered or may have suffered a head injury such as mild Traumatic Brain Injury (TBI) |
CN112175079A (en) * | 2020-10-10 | 2021-01-05 | 武汉华美生物工程有限公司 | Preparation method and application of multifunctional anti-GFAP monoclonal antibody |
CN112505329A (en) * | 2020-10-20 | 2021-03-16 | 山东第一医科大学(山东省医学科学院) | Application of mGluR1a breakage and early warning detection reagent for late-onset cerebral ischemia after subarachnoid hemorrhage |
EP4252243A2 (en) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
US20220308053A1 (en) * | 2021-03-29 | 2022-09-29 | Euroimmun Medizinische Labordiagnostika Ag | Method and reagents for the detection of an autoantibody |
CN113238045B (en) * | 2021-04-27 | 2021-12-28 | 南方医科大学南方医院 | Applications of CRMP2 and anti-CRMP 2 antibody |
CN113671179B (en) * | 2021-09-02 | 2023-10-03 | 中国科学院深圳先进技术研究院 | Kit for detecting KCNAB2 autoantibody as well as detection method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
EP1519194A1 (en) * | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20050260697A1 (en) * | 2004-04-15 | 2005-11-24 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
US20050260654A1 (en) * | 2004-04-15 | 2005-11-24 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
WO2010019553A2 (en) * | 2008-08-11 | 2010-02-18 | Banyan Biomarkers, Inc. | Biomarker detection process and assay of neurological condition |
-
2011
- 2011-06-17 WO PCT/US2011/040998 patent/WO2011160096A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003016910A1 (en) * | 2001-08-20 | 2003-02-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
EP1519194A1 (en) * | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | Use of gfap for identification of intracerebral hemorrhage |
US20050260697A1 (en) * | 2004-04-15 | 2005-11-24 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
US20050260654A1 (en) * | 2004-04-15 | 2005-11-24 | University Of Florida Research Foundation, Inc. | Neural proteins as biomarkers for nervous system injury and other neural disorders |
WO2010019553A2 (en) * | 2008-08-11 | 2010-02-18 | Banyan Biomarkers, Inc. | Biomarker detection process and assay of neurological condition |
Also Published As
Publication number | Publication date |
---|---|
WO2011160096A2 (en) | 2011-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011160096A3 (en) | Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition | |
WO2010019553A3 (en) | Biomarker detection process and assay of neurological condition | |
WO2011032155A3 (en) | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury | |
WO2010046443A3 (en) | Methods for detection and diagnosis of a bone or cartilage disorder | |
BR112014031365A2 (en) | methods of detecting disease or conditions | |
EP3355059A3 (en) | Biomarker assay of neurological condition | |
WO2012054588A3 (en) | Conduit-containing devices and methods for analyte processing and detection | |
WO2012004790A3 (en) | Nucleic acid aptamer-based detection methods characterized by signal enhancement | |
EP2569635A4 (en) | Methods for diagnosing and treating encephalitis or epilepsy | |
WO2013052505A3 (en) | Methods and devices for assessing risk to a putative offspring of developing a condition | |
BR112014032304A2 (en) | sandwich method, system and assay for the quantitative or qualitative determination of a target component in a liquid sample, kit for preparing a liquid sample, and microfluidic device. | |
WO2013009703A8 (en) | Antibodies, kit and method for detecting amyloid beta oligomers | |
WO2011005893A3 (en) | Biomarkers and methods for detecting alzheimer's disease | |
WO2011062469A8 (en) | Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker | |
BR112015008473A2 (en) | apparatus and method for determining the amount of a target protein and / or other types of biomarkers or analytes present in a sample | |
WO2011137388A3 (en) | Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample | |
WO2013128500A9 (en) | Die-cast product strength evaluation method and die-cast product | |
WO2012040500A3 (en) | Direct blood assay for detection of circulating microrna in cancer patients | |
WO2013167727A3 (en) | Method for determining arthritis relapse risk | |
SG10201806729VA (en) | Novel assay to detect human periostin | |
WO2015042326A3 (en) | Methods for detection and treatment of neurodegenerative diseases | |
WO2016205828A3 (en) | Role of citrullination in diagnosing diseases | |
WO2013064702A3 (en) | Probes for diagnosis and monitoring of neurodegenerative disease | |
GB201119585D0 (en) | Assay | |
WO2011113813A3 (en) | Assay for analytes based on aggregation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11796565 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11796565 Country of ref document: EP Kind code of ref document: A2 |